US Patent

US9180095 — Formulation of diclofenac

Method of Use · Assigned to Iceutica Pty Ltd · Expires 2030-04-23 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for producing particles of diclofenac and using them in medicaments for treating animals, including humans.

USPTO Abstract

The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.

Drugs covered by this patent

Voltaren (DICLOFENAC) · Hisamitsu Pharmaceutical Co., Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-55`	—	Voltaren
`U-55`	—	Voltaren

Patent Metadata

Patent number: US9180095
Jurisdiction: US
Classification: Method of Use
Expires: 2030-04-23
Drug substance claim: No
Drug product claim: No
Assignee: Iceutica Pty Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.